logo-loader
viewSynairgen PLC

Synairgen planning winter trial as it develops inhaled interferon beta drug for COPD

Richard Marsden, chief executive of Synairgen plc (LON:SNG) tells Proactive they're to  develop their inhaled interferon beta drug SNG001 as a potential treatment for chronic obstructive pulmonary disease (COPD) after a review of data indicated it can boost the lungs’ antiviral capabilities.

A short trial is being planned this winter to test the COPD potential.

Marsden also discusses their upcoming LOXL2 trial.

PXS-5382A, an inhibitor that aids breathing in patients by targeting the LOXL2 enzyme, is being developed with Australian firm Pharmaxis.

Results from the Phase I trial are scheduled for the middle of 2018, after which the aim is to find a partner to license the drug due to size of the potential market and number of indications it could address.

Quick facts: Synairgen PLC

Price: 41.5 GBX

AIM:SNG
Market: AIM
Market Cap: £62.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read